MLchartDataset catalogue

LOXO-101

Term · Oncology and biomedicine · MLC-T-ONC-004958

A drug used to treat adults and children with certain types of solid tumors that have spread or cannot be removed by surgery and have the NTRK gene fusion. It is also being studied in the treatment of other types of cancer. LOXO-101 blocks the TRK protein, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called larotrectinib sulfate, Trk inhibitor LOXO-101, and Vitrakvi.

Table 1. Record
IdentifierMLC-T-ONC-004958
FieldOncology and biomedicine
Expansionslarotrectinib sulfate; Trk inhibitor LOXO-101; Vitrakvi
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004958",
  "term": "LOXO-101",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults and children with certain types of solid tumors that have spread or cannot be removed by surgery and have the NTRK gene fusion. It is also being studied in the treatment of other types of cancer. LOXO-101 blocks the TRK protein, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called larotrectinib sulfate, Trk inhibitor LOXO-101, and Vitrakvi.",
  "expansions": [
    "larotrectinib sulfate",
    "Trk inhibitor LOXO-101",
    "Vitrakvi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/loxo-101/"
}

Record 10,334 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.